Contribution of receptor negative versus receptor defective mutations in the LDL-receptor gene to angiographically assessed coronary artery disease among young (25-49 years) versus middle-aged (50-64 years) men

Atherosclerosis

Volumn 143, Issue 1, 1999, Pages 153-161

  Gaudet, Daniel ^a,b   Vohl, Marie Claude ^a,b   Couture, Patrick ^b   Moorjani, Sital ^b   Tremblay, Gérald ^a   Perron, Patrice ^a   Gagné, Claude ^a,b   Després, Jean Pierre ^b  

^a CHICOUTIMI HOSPITAL   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Coronary artery disease; Familial hypercholesterolemia; LDL receptor

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; CORONARY RISK; FAMILIAL DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGE FACTORS; CORONARY ANGIOGRAPHY; CORONARY DISEASE; FRANCE; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPIDS; LIPOPROTEINS; LOGISTIC MODELS; MALE; MIDDLE AGED; MUTATION; QUEBEC; RECEPTORS, LDL; RISK FACTORS;

EID: 0033030089     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00268-8     Document Type: Article

References (48)

1. Lowel H., Dobson A., Keil U. et al. Coronary heart disease case fatality in four countries; a community study. Circulation. 88:1993;2524-2531.
2. Pisa Z. Trends in cardiovascular disease mortality in industrialized countries since 1950, Health Stat Q 1988;41(3-4):155-78.
3. Nicholls E., Nair C., MacWilliam L., Moen J., Mao Y. Cardiovascular disease mortality in Canada. Stat. Can. Ottawa. 77:1988;285-290.
4. Beaglehole R. International trends in coronary heart disease mortality; morbidity; and risk factors. Epidemiol. Rev. 12:1990;1-15.
5. Levy D., Wilson P.W., Anderson K.M., Castelli W.P. Stratifying the patient at risk from coronary disease; new insights from the Framingham Heart Study. Am. Heart. J. 119:1990;712-717.
6. Assmann G., Frick M.H. Redefining risk factors for coronary heart disease: the benefit of regulating lipoprotein. Drugs. 40:1990;1-56.
7. The lipid research clinics coronary primary prevention trial results. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering (LRC-CPPT). J Am Med Assoc 1984;151:365-74.
8. National cholesterol education program expert panel. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Circulation 1994;89:1329-37.
9. Stamler J., Wentworth D., Neaton J.D. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention trial (MRFIT). J. Am. Med. Assoc. 256:1986;2823-2828.
10. Martin M.J., Hulley S.B., Browner W.S., Kuller L.H., Wentworth D. Serum cholesterol; blood pressure; and mortality: implications from a cohort of 361 662 men. Lancet. 2:1986;933-936.
11. Kwiterovich P.O., Coresh J., Bachorik P.S. Prevalence of hyperbeta lipoproteinemia and other lipoprotein phenotypes in men (aged<50 years) and women (aged<60 years) with coronary artery disease. Am. J. Cardiol. 71:1993;631-639.
12. Genest J.J. Jr., McNamara J.R., Ordovas J.M. et al. Lipoprotein cholesterol; apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J. Am. Coll. Cardiol. 19:1992;792-802.
13. Schaefer E.J., Genest J.J. Jr., Ordovas J.M., Salem D.N., Wilson P.W.F. Familial lipoprotein disorders and premature coronary artery disease. Curr. Opin. Lipidol. 4:1993;288-298.
14. Reymer P.W., Gagné E., Groenemeyer B.E. et al. A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis. Nat. Genet. 10:1995;28-34.
15. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Basis of Inherited Disease. New York: McGraw-Hill, 1995:1981-2030.
16. Torres A.L., Moorjani S., Vohl M.C., Gagné C., Lamarche B., Brun L.D., Lupien P.J., Després J.P. Heterozygous familial hypercholesterolemia in children: low-density lipoprotein receptor mutational analysis and variation in the expression of plasma lipoprotein-lipid concentrations. Atherosclerosis. 126:1996;163-171.
17. Vohl M.C., Gaudet D., Moorjani S. et al. Comparison of the effect of two low-density-lipoprotein receptor class mutations on coronary heart disease among French-Canadian patients heterozygotes for familial hypercholesterolemia. Eur. J. Clin. Invest. 27:1997;366-373.
18. Vohl M.C., Moorjani S., Roy M. et al. Geographical distribution of French Canadian low-density lipoprotein receptor gene mutations in the province of Quebec. Clin. Genet. 52:1997;1-6.
19. Gaudet D., Tremblay G., Perron P., Gagné C., Ouadahi Y., Moorjani S. Hypercholesterolemia in Eastern Quebec: Is it a public health issue? Union. Med. Can. 124:1995;54-60.
20. Hobbs H.H., Brown M.S., Goldstein J.L. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum. Mutat. 1:1992;445-466.
21. Veillette S., Perron M., Hébert G. La mortalité intra-urbaine par maladies de l'appareil circulatoire: une approche écologique à micro-échelle. Union. Med. Can. 124:1995;54-60.
22. Lipid Research Clinics Program epidemiology committee. Plasma lipid distributions in selected North American populations: the Lipid Research Clinics Prevalence Study. Circulation 1979;60:427-39.
23. Rifkind B.M., Segal P. Lipid research clinics program reference values for hyperlipidemia and hypolipidemia. J. Am. Med. Assoc. 250:1983;1869-1872.
24. National Diabetes Data Group. Classification and diagnosis of diabetes and other categories of glucose intolerance. Diabetes 1979;28:1039-57.
25. Desbuquois B., Aurbach G.D. Use of polyethylene glycol to separate free antibody-bound peptide hormones in radioimmunoassays. J. Clin. Endocrinol. Metab. 37:1971;732-738.
26. Standardization of anthropometric measurements. in: Lohman T, Roche A, Martorel R, editors. The Airlie (VA) Consensus Conference. Human Kinetics Publishers, 1988:39-80.
27. Burstein M., Samaille J. Sur un dosage rapide du cholesterol lié aux alpha et aux bêta lipoprotéines du sérum. Clin. Chem. Acta. 5:1960;309.
28. McNamara J.R., Schaefer E.J. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fraction. Clin. Chim. Acta. 166:1987;1-8.
29. Warnick G.R., Benderson J., Albers J.J. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density lipoprotein cholesterol. Clin. Chem. 28:1982;1379-1387.
30. Friedewald W.T., Levy R.I., Frederickson D.S. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18:1972;499-502.
31. Laurell C.B. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal. Biochem. 15:1966;42.
32. Ma Y., Bétard C., Roy M., Davignon J., Kessling A. Identification of a second 'French Canadian' LDL receptor gene deletion and development of a rapid method to detect both deletions. Clin. Genet. 36:1989;219-228.
33. Leitersdorf E., Tobin E.J., Davignon J., Hobbs H.H. Common low-density lipoprotein receptor mutations in the French Canadian population. J. Clin. Invest. 85:1990;1014-1023.
34. Hobbs H.H., Michael M.D., Brown M.S., Russell D.W., Davignon J., Goldstein J.L. Deletion in the gene for the low-density-lipoprotein receptor in a majority of french canadians with familial hypercholesterolemia. New. Engl. J. Med. 317:1987;734-737.
35. Simard J., Moorjani S., Vohl M.C. et al. Detection of a novel mutation (stop 468) in exon 10 of the low-density lipoprotein receptor gene causing familial hypercholesterolemia among French Canadians. Hum. Mol. Genet. 3:1994;1689-1691.
36. Couture P, Vohl MC, Gagné C, et al. Identification of three mutations in the low-density lipoprotein receptor gene causing familial hypercholesterolemia among French-Canadians, Hum Mutat 1998;Suppl 1(6):S226-S231.
37. Vohl M.C., Couture P., Moorjani S. et al. Rapid restriction fragment analysis for screening four point mutations of the low-density lipoprotein receptor gene in French Canadians. Hum. Mutat. 6:1995;243-246.
38. Gagné C., Moorjani S., Brun D., Toussaint M., Lupien P.J. Heterozygous familial hypercholesterolemia. Relationship between plasma lipids; lipoproteins; clinical manifestations and ischaemic heart disease in men and women. Atherosclerosis. 34:1979;13-24.
39. Mabuchi H, Koizumi J, Shimuzu M, Takeda R, Hokuriku FH, CHD study group: development of coronary disease in familial hypercholesterolemia, Circulation 1989;79:225-32.
40. Ferrières J., Lambert J., Lussier-Cacan S., Davignon J. Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation. Circulation. 92:1995;290-295.
41. McGill D.A., Talsma P., Ardlie N.G. Relationship of blood cholesterol and apoprotein B levels to angiographically defined coronary artery disease in young males. Coron. Artery. Dis. 4:1993;261-270.
42. Moorjani S., Roy M., Torres A.L. et al. Mutations of low-density-lipoprotein-receptor gene, variation in plasma cholesterol, and expression of coronary heart disease in homozygous familial hypercholesterolaemia. Lancet. 341:1993;1303-1306.
43. Bétard C., Kessling A.M., Roy M., Davignon J. Influence of genetic variability in the nondeletion LDL-receptor allele on phenotypic variation in French-Canadian familial hypercholesterolemia heterozygotes sharing a 'null' LDL-receptor gene defect. Atherosclerosis. 119:1996;43-55.
44. Gaudet D., Vohl M.C., Perron P. et al. Relationships of abdominal obesity and hyperinsulinemia to angiographically assessed coronary artery disease in men with known mutations in the LDL-receptor gene. Circulation. 97:1998;871-877.
45. Williams R.R., Hasstedt S.J., Wilson D.E., Ash K.O., Yanowitz F.F., Reiber G.E., Kuida H. Evidence that men with familial hypercholesterolemia can avoid early coronary death; an analysis of 77 gene carriers in four utah pedigrees. J. Am. Med. Assoc. 255(2):1986;219-224.
46. Hill J.S., Hayden M.R., Frohlich J., Pritchard P.H. Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia. Arterioscler. Thromb. 11:1991;290-297.
47. Hegele R.A., Sutherland S., Wu L., Emi M., Hopkins P.N., Williams R.R., Lalouel J.-M. The effect of genetic determinants of low density lipoprotein levels on lipoprotein (a). Clin. Invest. Med. 14:1991;146-152.
48. Carmena R., Lussier-Cacan S., Roy M. et al. Lp(a) levels and atherosclerotic vascular disease in a sample of patients with familial hypercholesterolemia sharing the same gene defect. Arterioscler. Thromb. Vasc. Biol. 16:1996;129-136.